Answers are grounded in this paper and cite their sources.
Disease-modifying effect of efruxifermin in compensated cirrhosis due to MASH: To miss the forest for the tree(s)The first effective treatment for metabolic dysfunctionassociated steatohepatitis (MASH)-related compensated cirrhosis is still awaited.Just recently, the SYMMETRY phase IIb study on efruxifermin, a bivalent fibroblast growth factor 21 (FGF21) analogue, has been published, investigating fibrosis improvement without worsening of MASH after 36 (primary endpoint) and 96 weeks (secondary endpoint).1 Following an overwhelmingly positive press release in January 2025, the intention-to-treat (ITT) analysis including 181 patients (78% with MASH, 22% with cryptogenic cirrhosis, Table 1) showed no significant differences for the primary endpoint (13% [placebo] vs. 18% [28 mg] vs. 19% [50 mg]), but a signal towards an improvement after 96 weeks: 11% vs. 21% vs. 29%.As expected, the per protocol analysis for the same time point (comprising only 134/181 patients) indicated numerically higher response rates (15% vs. 29% vs. 39%), which are also supported by consistent improvements in non-invasive fibrosis biomarkers.After a period of trials and tribulations in MASHrelated compensated cirrhosis (Table 1), these signals should not be underestimated.Choosing histological cirrhosis regression as the primary endpoint sets the bar very high.Focusing on this single aspect (i.e.'tree') poses the risk of overlooking the potential 'forest' of clinically meaningful benefit that -in case of efruxifermin -will hopefully be revealed by the ongoing phase III clinical trial capturing direct endpoints (Fig. 1).From a clinical and patient-centric perspective, compensated cirrhosis/F4 is not a uniform condition.It rather represents a continuum of decompensation (i.e.morbidity) probability ranging from negligible to substantial in individual patients, with portal hypertension being the key surrogate of this risk.3,4 Specifically, clinically significant portal hypertension (CSPH, as defined by a minimally invasively assessed hepatic venous pressure gradient > -10 mmHg) denotes the hemodynamic threshold for hepatic decompensation.3,4 In clinical practice, the probability of CSPH is estimated by non-invasive models, 5 such as the ANTICIPATE±NASH or the Non-Invasive CSPH Estimated Risk (NICER) models, with the latter attaining a discriminative ability as high as �0.9.6 This enables quantification of an individual's decompensation risk, which affects the absolute risk reduction/number-needed to treat of diseasemodifying treatments.
No takes yet. Share an insight, caveat, or question.
Mandorfer et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: